Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

Background: Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. Objective: We assessed a wide series of GCA treated with TCZ, to evaluate its role in the prevention of ne...

Descripción completa

Detalles Bibliográficos
Autores: Loricera, J, Castañeda, S, Moriano, C, Narváez, J, Aldasoro, V, Maiz, O, Melero, R, Villa, I, Vela, P, Romero-Yuste, S, Callejas, JL, de Miguel, E, Galíndez-Agirregoikoa, E, Sivera, F, Fernández-López, JC, Galisteo, C, Ferraz-Amaro, I, Sánchez-Martín, J, Sánchez-Bilbao, L, Calderón-Goercke, M, Casado, A, Hernández, JL, González-Gay, MA, Blanco, R
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p16354
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/16354
Access Level:acceso abierto
Palabra clave:giant cell arteritis
large-vessel vasculitis
tocilizumab
visual involvement
id ES_10bec0f64ae91ba5a7eea0eebabfb554
oai_identifier_str oai:fisabio.fundanetsuite.com:p16354
network_acronym_str ES
network_name_str España
repository_id_str
spelling Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patientsLoricera, JCastañeda, SMoriano, CNarváez, JAldasoro, VMaiz, OMelero, RVilla, IVela, PRomero-Yuste, SCallejas, JLde Miguel, EGalíndez-Agirregoikoa, ESivera, FFernández-López, JCGalisteo, CFerraz-Amaro, ISánchez-Martín, JSánchez-Bilbao, LCalderón-Goercke, MCasado, AHernández, JLGonzález-Gay, MABlanco, Rgiant cell arteritislarge-vessel vasculitistocilizumabvisual involvementBackground: Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. Objective: We assessed a wide series of GCA treated with TCZ, to evaluate its role in the prevention of new visual complications and its efficacy when this manifestation was already present before the initiation of TCZ. Design: This is an observational multicenter study of patients with GCA treated with TCZ. Methods: Patients were divided into two subgroups according to the presence or absence of visual involvement before TCZ onset. Visual manifestations were classified into the following categories: transient visual loss (TVL), permanent visual loss (PVL), diplopia, and blurred vision. Results: Four hundred seventy-one GCA patients (mean age, 74 +/- 9 years) were treated with TCZ. Visual manifestations were observed in 122 cases (26%), of which 81 were present at TCZ onset: PVL (n = 60; unilateral/bilateral: 48/12), TVL (n = 17; unilateral/bilateral: 11/6), diplopia (n = 2), and blurred vision (n = 2). None of the patients without previous visual involvement or with TVL had new episodes after initiation of TCZ, while only 11 out of 60 (18%) patients with PVL experienced some improvement. The two patients with diplopia and one of the two patients with blurred vision improved. Conclusion: TCZ may have a protective effect against the development of visual complications or new episodes of TVL in GCA. However, once PVL was established, only a few patients improved.SAGE PUBLICATIONS LTD2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/16354Therapeutic Advances in Musculoskeletal DiseaseISSN: 1759720XISSNe: 17597218reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p163542026-06-11T12:45:17Z
dc.title.none.fl_str_mv Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
title Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
spellingShingle Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
Loricera, J
giant cell arteritis
large-vessel vasculitis
tocilizumab
visual involvement
title_short Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
title_full Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
title_fullStr Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
title_full_unstemmed Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
title_sort Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
dc.creator.none.fl_str_mv Loricera, J
Castañeda, S
Moriano, C
Narváez, J
Aldasoro, V
Maiz, O
Melero, R
Villa, I
Vela, P
Romero-Yuste, S
Callejas, JL
de Miguel, E
Galíndez-Agirregoikoa, E
Sivera, F
Fernández-López, JC
Galisteo, C
Ferraz-Amaro, I
Sánchez-Martín, J
Sánchez-Bilbao, L
Calderón-Goercke, M
Casado, A
Hernández, JL
González-Gay, MA
Blanco, R
author Loricera, J
author_facet Loricera, J
Castañeda, S
Moriano, C
Narváez, J
Aldasoro, V
Maiz, O
Melero, R
Villa, I
Vela, P
Romero-Yuste, S
Callejas, JL
de Miguel, E
Galíndez-Agirregoikoa, E
Sivera, F
Fernández-López, JC
Galisteo, C
Ferraz-Amaro, I
Sánchez-Martín, J
Sánchez-Bilbao, L
Calderón-Goercke, M
Casado, A
Hernández, JL
González-Gay, MA
Blanco, R
author_role author
author2 Castañeda, S
Moriano, C
Narváez, J
Aldasoro, V
Maiz, O
Melero, R
Villa, I
Vela, P
Romero-Yuste, S
Callejas, JL
de Miguel, E
Galíndez-Agirregoikoa, E
Sivera, F
Fernández-López, JC
Galisteo, C
Ferraz-Amaro, I
Sánchez-Martín, J
Sánchez-Bilbao, L
Calderón-Goercke, M
Casado, A
Hernández, JL
González-Gay, MA
Blanco, R
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv giant cell arteritis
large-vessel vasculitis
tocilizumab
visual involvement
topic giant cell arteritis
large-vessel vasculitis
tocilizumab
visual involvement
description Background: Visual involvement is the most feared complication of giant cell arteritis (GCA). Information on the efficacy of tocilizumab (TCZ) for this complication is scarce and controversial. Objective: We assessed a wide series of GCA treated with TCZ, to evaluate its role in the prevention of new visual complications and its efficacy when this manifestation was already present before the initiation of TCZ. Design: This is an observational multicenter study of patients with GCA treated with TCZ. Methods: Patients were divided into two subgroups according to the presence or absence of visual involvement before TCZ onset. Visual manifestations were classified into the following categories: transient visual loss (TVL), permanent visual loss (PVL), diplopia, and blurred vision. Results: Four hundred seventy-one GCA patients (mean age, 74 +/- 9 years) were treated with TCZ. Visual manifestations were observed in 122 cases (26%), of which 81 were present at TCZ onset: PVL (n = 60; unilateral/bilateral: 48/12), TVL (n = 17; unilateral/bilateral: 11/6), diplopia (n = 2), and blurred vision (n = 2). None of the patients without previous visual involvement or with TVL had new episodes after initiation of TCZ, while only 11 out of 60 (18%) patients with PVL experienced some improvement. The two patients with diplopia and one of the two patients with blurred vision improved. Conclusion: TCZ may have a protective effect against the development of visual complications or new episodes of TVL in GCA. However, once PVL was established, only a few patients improved.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/16354
url https://fisabio.portalinvestigacion.com/publicaciones/16354
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
dc.source.none.fl_str_mv Therapeutic Advances in Musculoskeletal Disease
ISSN: 1759720X
ISSNe: 17597218
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403527155023872
score 15,81155

Similares en LA Referencia